221 related articles for article (PubMed ID: 32709869)
1. Therapeutic paradigm of dual targeting VEGF and PDGF for effectively treating FGF-2 off-target tumors.
Hosaka K; Yang Y; Seki T; Du Q; Jing X; He X; Wu J; Zhang Y; Morikawa H; Nakamura M; Scherzer M; Sun X; Xu Y; Cheng T; Li X; Liu X; Li Q; Liu Y; Hong A; Chen Y; Cao Y
Nat Commun; 2020 Jul; 11(1):3704. PubMed ID: 32709869
[TBL] [Abstract][Full Text] [Related]
2. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
3. Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects.
Li D; Xie K; Zhang L; Yao X; Li H; Xu Q; Wang X; Jiang J; Fang J
Cancer Lett; 2016 Jul; 377(2):164-73. PubMed ID: 27130666
[TBL] [Abstract][Full Text] [Related]
4. Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling.
Hasumi Y; Kłosowska-Wardega A; Furuhashi M; Ostman A; Heldin CH; Hellberg C
Int J Cancer; 2007 Dec; 121(12):2606-14. PubMed ID: 17691110
[TBL] [Abstract][Full Text] [Related]
5. VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling.
Kano MR; Morishita Y; Iwata C; Iwasaka S; Watabe T; Ouchi Y; Miyazono K; Miyazawa K
J Cell Sci; 2005 Aug; 118(Pt 16):3759-68. PubMed ID: 16105884
[TBL] [Abstract][Full Text] [Related]
6. Scopoletin, an active principle of tree tobacco (Nicotiana glauca) inhibits human tumor vascularization in xenograft models and modulates ERK1, VEGF-A, and FGF-2 in computer model.
Tabana YM; Hassan LE; Ahamed MB; Dahham SS; Iqbal MA; Saeed MA; Khan MS; Sandai D; Majid AS; Oon CE; Majid AM
Microvasc Res; 2016 Sep; 107():17-33. PubMed ID: 27133199
[TBL] [Abstract][Full Text] [Related]
7. Sequential delivery of VEGF, FGF-2 and PDGF from the polymeric system enhance HUVECs angiogenesis in vitro and CAM angiogenesis.
Bai Y; Bai L; Zhou J; Chen H; Zhang L
Cell Immunol; 2018 Jan; 323():19-32. PubMed ID: 29111157
[TBL] [Abstract][Full Text] [Related]
8. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
9. Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B.
Wroblewski M; Bauer R; Cubas Córdova M; Udonta F; Ben-Batalla I; Legler K; Hauser C; Egberts J; Janning M; Velthaus J; Schulze C; Pantel K; Bokemeyer C; Loges S
Nat Commun; 2017 Aug; 8(1):269. PubMed ID: 28814715
[TBL] [Abstract][Full Text] [Related]
10. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation.
Ning S; Laird D; Cherrington JM; Knox SJ
Radiat Res; 2002 Jan; 157(1):45-51. PubMed ID: 11754641
[TBL] [Abstract][Full Text] [Related]
11. A role for VEGF as a negative regulator of pericyte function and vessel maturation.
Greenberg JI; Shields DJ; Barillas SG; Acevedo LM; Murphy E; Huang J; Scheppke L; Stockmann C; Johnson RS; Angle N; Cheresh DA
Nature; 2008 Dec; 456(7223):809-13. PubMed ID: 18997771
[TBL] [Abstract][Full Text] [Related]
12. LHT7, a chemically modified heparin, inhibits multiple stages of angiogenesis by blocking VEGF, FGF2 and PDGF-B signaling pathways.
Chung SW; Bae SM; Lee M; Al-Hilal TA; Lee CK; Kim JK; Kim IS; Kim SY; Byun Y
Biomaterials; 2015 Jan; 37():271-8. PubMed ID: 25453957
[TBL] [Abstract][Full Text] [Related]
13. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
14. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
15. Lenvatinib for effectively treating antiangiogenic drug-resistant nasopharyngeal carcinoma.
Sun Q; Wang Y; Ji H; Sun X; Xie S; Chen L; Li S; Zeng W; Chen R; Tang Q; Zuo J; Hou L; Hosaka K; Lu Y; Liu Y; Ye Y; Yang Y
Cell Death Dis; 2022 Aug; 13(8):724. PubMed ID: 35985991
[TBL] [Abstract][Full Text] [Related]
16. Specific targeting of PDGFRβ in the stroma inhibits growth and angiogenesis in tumors with high PDGF-BB expression.
Tsioumpekou M; Cunha SI; Ma H; Åhgren A; Cedervall J; Olsson AK; Heldin CH; Lennartsson J
Theranostics; 2020; 10(3):1122-1135. PubMed ID: 31938055
[TBL] [Abstract][Full Text] [Related]
17. Effects of angiogenic growth factor combinations on retinal endothelial cells.
Castellon R; Hamdi HK; Sacerio I; Aoki AM; Kenney MC; Ljubimov AV
Exp Eye Res; 2002 Apr; 74(4):523-35. PubMed ID: 12076096
[TBL] [Abstract][Full Text] [Related]
18. Novel pharmacologic approaches to the prevention and treatment of ulcerative colitis.
Deng X; Szabo S; Khomenko T; Tolstanova G; Paunovic B; French SW; Sandor Z
Curr Pharm Des; 2013; 19(1):17-28. PubMed ID: 22950505
[TBL] [Abstract][Full Text] [Related]
19. Novel multi-targeted inhibitors suppress ocular neovascularization by regulating unique gene sets.
Yin X; Lin X; Ren X; Yu B; Liu L; Ye Z; Chen Q; Lee C; Lu W; Yu D; Li X
Pharmacol Res; 2019 Aug; 146():104277. PubMed ID: 31112749
[TBL] [Abstract][Full Text] [Related]
20. The Involvement of PDGF-B/PDGFRβ Axis in the Resistance to Antiangiogenic and Antivascular Therapy in Renal Cancer.
Cumpănas AA; Cimpean AM; Ferician O; Ceausu RA; Sarb S; Barbos V; Dema A; Raica M
Anticancer Res; 2016 May; 36(5):2291-5. PubMed ID: 27127135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
